SCHEMBL17019930

SCHEMBL17019930

CCCCC[C@@H](CO)NCc1c[nH]c2c(N)ncnc12

nearest known ligand 0.71

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ MTAP Q13126 15/20 0.71
▸ PNP P00491 2/20 0.47
▸ HPRT1 P00492 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22212753 0.99 MTAP (0.69) MTAPPNPHPRT1
SCHEMBL17019932 0.99 MTAP (0.69) MTAPPNPHPRT1
SCHEMBL22204046 0.99 MTAP (0.69) MTAPPNPHPRT1
SCHEMBL17009633 0.99 MTAP (0.69) MTAPPNPHPRT1
SCHEMBL22212762 0.97 MTAP (0.72) MTAPPNPHPRT1
SCHEMBL17019924 0.97 MTAP (0.72) MTAPPNPHPRT1
SCHEMBL17009657 0.97 MTAP (0.72) MTAPPNPHPRT1
SCHEMBL17020069 0.92 MTAP (0.75) MTAPPNPHPRT1
SCHEMBL17009700 0.87 MTAP (0.78) MTAPPNPHPRT1
SCHEMBL2251381 0.87 MTAP (0.81) MTAPPNPHPRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3104707-B1 TREATMENT OF H. PYLORI INFECTIONS USING MTAN INHIBITORS ALBERT EINSTEIN COLLEGE MEDICINE INC (US) 2020-07-15 — — EP disclosed
EP-3104707-B1 TREATMENT OF H. PYLORI INFECTIONS USING MTAN INHIBITORS ALBERT EINSTEIN COLLEGE MEDICINE INC (US) 2020-07-15 — — EP disclosed
US-10294233-B2 Treatment of H. pylori infections using MTAN inhibitors ALBERT EINSTEIN COLLEGE OF MEDICINE (US) 2019-05-21 — — US disclosed
US-10294233-B2 Treatment of H. pylori infections using MTAN inhibitors ALBERT EINSTEIN COLLEGE OF MEDICINE (US) 2019-05-21 — — US disclosed
US-20190016730-A1 TREATMENT OF H. PYLORI INFECTIONS USING MTAN INHIBITORS ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) 2019-01-17 — — US disclosed
US-20190016730-A1 TREATMENT OF H. PYLORI INFECTIONS USING MTAN INHIBITORS ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) 2019-01-17 — — US disclosed
US-10118928-B2 Treatment of H. pylori infections using MTAN inhibitors ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) 2018-11-06 — — US disclosed
US-20170166571-A1 TREATMENT OF H. PYLORI INFECTIONS USING MTAN INHIBITORS ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) 2017-06-15 — — US disclosed
US-20170166571-A1 TREATMENT OF H. PYLORI INFECTIONS USING MTAN INHIBITORS ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) 2017-06-15 — — US disclosed
US-20170166571-A1 TREATMENT OF H. PYLORI INFECTIONS USING MTAN INHIBITORS ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) 2017-06-15 — — US disclosed
WO-2015123101-A1 TREATMENT OF H. PYLORI INFECTIONS USING MTAN INHIBITORS ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2015-08-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10118928-B2 Treatment of H. pylori infections using MTAN inhibitors MTAP, UNG, PNP MTAP 1/4885PNP 3/4885HPRT1 39/4885
US-20170166571-A1 TREATMENT OF H. PYLORI INFECTIONS USING MTAN INHIBITORS MTAP, PNP, UNG MTAP 1/4885PNP 2/4885HPRT1 40/4885
US-10294233-B2 Treatment of H. pylori infections using MTAN inhibitors MTAP, PNP, UNG MTAP 1/4885PNP 2/4885HPRT1 40/4885
US-20190016730-A1 TREATMENT OF H. PYLORI INFECTIONS USING MTAN INHIBITORS MTAP, PNP, UNG MTAP 1/4885PNP 2/4885HPRT1 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback